ENESTop = A clinical research study evaluating the possibility to stop the drug nilotinib in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib treatment
Study title
ENESTop = A clinical research study evaluating the possibility to stop the drug nilotinib in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib treatment
Scientific title
A phase II, single arm, open label study of treatment-free remission after achieving sustained MR4.5 on nilotinib (EudraCT 2012-003186-18; ClinicalTrials.gov NCT01698905)
Type of study
Treatment free remission trial
Current status
Recruitment completed
What is the purpose of the study
To stop nilotinib treatment in CML-CP patients (who started treatment with ≥ 4 weeks of imatinib, then switched to nilotinib for a minimum of 2 years (with minimum combined duration on imatinib and nilotinib ≥ 3 years), and achieved MR4.5 on nilotinib) who maintained MR4.5 during the 1 year nilotinib treatment on study.
Key inclusion criteria
Chronic myeloid leukemia (CML) chronic phase patients.
Potential participants should have been diagnosed with CML and should have received first-line treatment with imatinib, then switched to nilotinib for at least 2 years prior to study entry with the combined time on imatinib and nilotinib being at least 3 years. Patients must not have documented MR4.5 at the time of switch to nilotinib, and should have achieved MR4.5 on nilotinib.
Key exclusion criteria
Where can I find additional information
Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)
Study description in the US register ClinicalTrials.gov, a service of the U.S. National Institutes of Health
“ENESTop brochure: Answers to frequently asked questions patients may have about the study of and treatment with nilotinib”
“ENESTop brochure “Molecular response: a measure of treatment success in Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)“
Study sponsor
Novartis Pharma AG
Scientific lead / contact
Yu Jin
Clinical Trial Head
Yu-1.jin@novartis.com
Rafik Fellague-Chebra
Medical Director
rafik.fellague-chebra@novartis.com
Principal investigator
Tim Hughes
Francois-Xavier Mahon
Dong-Wook Kim
Study centers / principal investigators
Argentina
Buenos Aires
Fundaleu
Buenos Aires
Hospital Jose Maria Ramos Mejia
Australia
Box Hill
Box Hill Hospital
Adelaide
Royal Adelaide Hospital
St. Leonards
Royal North Shore Hospital
Belgium
Antwerp
ZNA Stuivenberg Hematology/Oncology
Gent
Universitair Ziekenhuis Gent
Haine-saint-Paul
Jolimont
Brazil
Campinas
Universidade de Campinas
Belo Horizonte
Hospital das Clínicas de Belo Horizonte – UFMG
Goiania
Hospital Universitário de Gôiania
Curitiba
Hospital Santa Casa de Curitiba PUCPR
Porto Alegre
Hospital de Clínicas de Porto Alegre
Rio de Janeiro
Instituto Estadual de Hematologia Arthur de Siqueira Cavalca
São Paulo
Hospital das clinicas da Faculdade de Medicina da USP
São Paulo
Irmandade de Santa Casa de Misericordia de Sao Paulo
Rio de Janeiro
Instituo Nacional do Cancer
São Paulo
Casa de Saude Santa Marcelina
Canada
Toronto
Princess Margaret Hospital
Hamilton
The Juravinski Cancer Clinic
Montreal
Hopital Maisonneuve-Rosemont
Québec
Hopital de I’Enfant Jesus
France
Bordeaux
Institut Bergonie
Pierre-Benite Cédex
Centre Hospitalier Lyon-Sud
Vandoeuvre les Nancy
CHU Brabois
Grenoble Cedex 9
Hopital Albert Michallon
Strasbourg Cedex
GH St. Vincent-Clinique Ste Anne
Germany
Berlin
Charité Universitätsmedizin Berlin
Ulm
Universitätsklinikum Ulm
Potsdam
MVZ für Blut- und Krebserkrankungen Potsdam
Mannheim
Universitätsmedizin Mannheim
Heilbronn
Onkologie Heilbronn
Leipzig
Universitätsklinikum Leipzig
Greece
Heraklion Crete
University General Hospital of Heraklion
Athens
Attikon Univ. Gen. Hospital of Athens
Athens, Neo Faliro
Metropolitan Hospital
Athens – GR
General Hospital of Athens Evangelismos
Larissa
University General Hospital of Larissa
Israel
Ramat Gan
The Chaim Sheba Medical Center
Petach Tikva
Rabin Medical Center
Haifa
Rambam Medical Center
Japan
Akita
Akita University Hospital
Fukuoka-city
Kyushu University Hospital
Nagoya
Aichi Cancer Center Hospital
Aomori
Aomori Prefecture Central Hospital
Kurume
Kurume University Hospital
Narita
Narita Red Cross Hospital
Chiba-city
Chiba University Hospital
Korea, Republic of
Seoul
Seoul St. Mary’s Hospital
Mexico
San Luis Potosí
Centro Regional de Enfermedades Oncologicas
México
Instituto Nacional de Cancerologia
Monterrey
Hospital y Clinica OCA
Netherlands
Amsterdam
VUMC Amsterdam
Poland
Krakow
Collegium Medicum Uniwersytetu Jagielonskiego (Krakow)
Gdansk
Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematolog
Warzawa
Instytut Hematologii i Transfuzjologi (Warszawa)
Russian Federation
Moscow
Hematological Scientific Center of RAMS
St. Petersburg
State Pavlov Medical University
St. Petersburg
Research Institute of Hematology and Blood Transfusion, 16
Singapore
Singapore General Hospital
Spain
Madrid
Hospital Universitario de la Princesa
Sevilla
Hospital Virgen del Rocio
Alicante
Hospital General Universitario de Alicante
Badalona
Hospital Universitario Germans Trias i Pujol
Santander
Hospital Universitario Marques de Valdecilla
Madrid
Hospital Ramon y Cajal
Madrid
Hospital Universitario La Paz
Santa Cruz de Tenerife
Hospital Universitario de Canarias
Tunisia
Tunis
Hôpital Aziza Othmana
United Kingdom
Liverpool
Royal Liverpool University Hospital
Nottingham
Nottingham City Hospital
Bournemouth
Royal Bournemouth Hospital
USA
Los Angeles
USC/Kenneth Norris Comprehensive Cancer Center
Indianapolis
Indiana Blood and Marrow Institute
Duarte
City of Hope National Medical Center
Baltimore
St. Agnes Hospital
Vancouver
Compass Oncology
Galveston
University of TX Medical Branch